ImpediMed

ImpediMed Depreciation & Amortization

The Depreciation & Amortization of ImpediMed (IPD.AX) as of Nov 12, 2026 is 4.56 M AUD. In the previous year, Depreciation & Amortization was 2.25 M AUD — a change of 102.57% (higher).

Depreciation & Amortization

4.56 MAUD

YoY

102.57%

Last updated:

Depreciation & Amortization of ImpediMed is 2025 4.56 M AUD. Depreciation & Amortization of ImpediMed was 2024 2.25 M AUD. It decreases by 102.57% higher compared to the previous year.

The ImpediMed Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2018
417,000.00 AUD
Jan 1, 2019
682,000.00 AUD
Jan 1, 2020
1.44 M AUD
Jan 1, 2021
1.70 M AUD
Jan 1, 2022
2.77 M AUD
Jan 1, 2023
2.47 M AUD
Jan 1, 2024
2.25 M AUD
Jan 1, 2025
4.56 M AUD
The ImpediMed Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
4.56 MAUD+102.57%
2.25 MAUD-8.67%
2.47 MAUD-10.91%
2.77 MAUD+62.88%
1.70 MAUD+18.38%
1.44 MAUD+110.56%
682,000.00AUD+63.55%
417,000.00AUD+63.53%
255,000.00AUD+38.59%
184,000.00AUD+24.32%
148,000.00AUD+34.55%
110,000.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Depreciation & Amortization of ImpediMed is 4.56 M AUD in 2025.

Depreciation & Amortization of ImpediMed changed from 2.25 M AUD to 4.56 M AUD, representing a 102.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ImpediMed

All Key Metrics — ImpediMed